Earnings roundup: GW Pharmaceuticals awaiting big CBD drug sales as it reports losses

Hemp Industry Daily
By Kristen NicholsFeb 28, 2019, 4:35 pm287 pts
GW Pharmaceuticals, the drugmaker behind the only federally approved CBD product, is still losing money, though it says it’s happy with early sales of its seizure control drug Epidiolex. Last summer, Epidiolex became the first cannabis-derived treatment approved by the U.S. Food and Drug Administration,…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Arkansas can enforce hemp-derived THC ban, appeals court rules 69

Chicago Police Can’t Search Vehicles Based on Smell of Raw Cannabis Under New Rules 68

Half-Year Retrospective: What Has Worked and What Hasn’t in Cannabis 68

Nova Scotians bought $127 worth of cannabis in 2024 as sales begin to level off 67

Nebraska Medical Cannabis Commission Proposal Will ‘Destroy Patient Access,’ Advocates Say 64

The PFAS Threat in Cannabis and Hemp: What You Need to Know 62

Circuit Court Ruling for Arkansas Renders Texas Governor’s Hemp Veto Argument Moot 61

World-Class Growing Solutions 57

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.